Pharmacy Drugs
Recent Posts
- Democrats Push Medical Device Liability Bill
- FDA Investigates Heparin Link in Two Delaware Deaths
- Conflict Of Interest Reported In 29 Percent Of Cancer Studies
- Interim Results Of Abbott’s PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir
- Survival For Prostate Cancer Patients Younger Than 50 Improved By Surgery
Random Posts
- Founder Of The Royal Pharmaceutical Society Commemorated In Tunbridge Wells
- Excess Body Weight Causes Over 124,000 New Cancers A Year In Europe
- Women Have Special Concerns With Prescription Medications
- DOR BioPharma Receives EMEA Agreement On The Design Of Its Confirmatory Phase 3 Clinical Trial Of OrBec(R) In GI GVHD
- Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data At ASCO Annual Meeting
- Men's Blood Pressure Increased By High-Sugar Diet
- Jazz Pharmaceuticals And UCB Announce Second Phase III Study Of Sodium Oxybate In Patients With Fibromyalgia Meets Primary Endpoints
- Chair Of General Pharmaceutical Council Is Welcomed By Society
- Pharmacists Have Solution To Address White House's Economic Case For Health Care Reform
- Royal Pharmaceutical Society Responds To Concerns Over Human Swine Flu, UK
Medtronic Issues Pacemaker Recall
Posted by: admin in Pharmacy Drugs on October 08th, 2009
LITTLE FALLS, N.J., June 12 — Certain pacemakers manufactured by Medtronic have been withdrawn from the market because of wiring problems, the FDA announced.
Of the more than 1.7 million Kappa and Sigma pacemakers implanted worldwide, about 21,300 are included in the recall.
They include devices in the Kappa Series 600/700/900 and Sigma Series 100/200/300 manufactured primarily between November 2000 and November 2002.
Patients can enter the serial number of their device at this Web site to find out whether it is included in the recall.
The FDA explained that the “devices may fail due to a separation of wires that connect the electronic circuit to other pacemaker components, such as the battery.”
In its letter to physicians, Medtronic estimated the failure rates of Kappa and Sigma pacemakers to be 1.1% and 4.8%, respectively.
In rare cases, patients who are pacemaker-dependent may experience serious injury or death resulting from the defect, the FDA said.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.